Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
VIDEO: Trends in Structural Heart Procedural Imaging | new EP ablation system enters U.S. trial
Monday, September 12, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

FDA approves trial for new type of thermal-ablation system to treat ventricular arrhythmias

The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.

READ MORE >
Thermedical SERF thermal ablation system for VT.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves trial for new type of thermal-ablation system to treat ventricular arrhythmias

Share on Twitter Share on Facebook Share on Linkedin
Thermedical SERF thermal ablation system for VT.
The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.
READ MORE >

VIDEO: Trends in structural heart procedural imaging - a discussion with Rebecca Hahn

Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.

READ MORE >
Interview with Rebecca T. Hahn, MD, Professor of Medicine at Columbia University Irving Medical Center, Chief Scientific Officer of the Echo Core Lab at the Cardiovascular Research Foundation and Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center. She discusses some of the trends of growing use of interventional echocardiographic guidance in transcatheter structural heart procedures, the growing number of tricuspid valve procedures, and use of 3D ICE.
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Trends in structural heart procedural imaging - a discussion with Rebecca Hahn

Share on Twitter Share on Facebook Share on Linkedin
Interview with Rebecca T. Hahn, MD, Professor of Medicine at Columbia University Irving Medical Center, Chief Scientific Officer of the Echo Core Lab at the Cardiovascular Research Foundation and Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center. She discusses some of the trends of growing use of interventional echocardiographic guidance in transcatheter structural heart procedures, the growing number of tricuspid valve procedures, and use of 3D ICE.
Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.
READ MORE >

FDA warns of a new malfunction risk with Abbott’s MitraClip devices

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

READ MORE >
The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. The results of the COAPT trial dropped like a thunderclap Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, with several cardiologists predicting the MitraClip device will have a swift and lasting impact on the treatment of heart failure patients.
Share on Twitter Share on Facebook Share on Linkedin

FDA warns of a new malfunction risk with Abbott’s MitraClip devices

Share on Twitter Share on Facebook Share on Linkedin
The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. The results of the COAPT trial dropped like a thunderclap Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, with several cardiologists predicting the MitraClip device will have a swift and lasting impact on the treatment of heart failure patients.
When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.
READ MORE >

DOACs after TAVR may put some patients at risk, new meta-analysis suggests

The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 

READ MORE >
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings
Share on Twitter Share on Facebook Share on Linkedin

DOACs after TAVR may put some patients at risk, new meta-analysis suggests

Share on Twitter Share on Facebook Share on Linkedin
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings
The new study, based on data from nearly 3,000 patients, compared DOACs such as rivaroxaban, apixaban and edoxaban with single and dual antiplatelet therapy. 
READ MORE >

VIDEO: 9 key areas where AI is being implemented in healthcare

Julius Bogdan, vice president and general manager of the Healthcare Information and Management Systems Society (HIMSS) Digital Health Advisory Team for North America, explains several key artificial intelligence (AI) trends he sees across healthcare.

READ MORE >
Julius Bogdan, vice president and general manager of the Healthcare Information and Management Systems Society (HIMSS) Digital Health Advisory Team for North America, explains several key artificial intelligence (AI) trends he sees across healthcare.
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: 9 key areas where AI is being implemented in healthcare

Share on Twitter Share on Facebook Share on Linkedin
Julius Bogdan, vice president and general manager of the Healthcare Information and Management Systems Society (HIMSS) Digital Health Advisory Team for North America, explains several key artificial intelligence (AI) trends he sees across healthcare.
Julius Bogdan, vice president and general manager of the Healthcare Information and Management Systems Society (HIMSS) Digital Health Advisory Team for North America, explains several key artificial intelligence (AI) trends he sees across healthcare.
READ MORE >

Aspartame, other artificial sweeteners linked to significant heart problems

These findings, researchers wrote, suggest that artificial sweeteners "should not be considered a healthy and safe alternative to sugar."

READ MORE >
Artificial sweeteners may be associated with a higher risk of cardiovascular disease (CVD), according to new research published in The BMJ. Aspartame intake was linked to a greater risk of cerebrovascular events and acesulfame potassium and sucralose were linked to a greater risk of coronary heart disease.
Share on Twitter Share on Facebook Share on Linkedin

Aspartame, other artificial sweeteners linked to significant heart problems

Share on Twitter Share on Facebook Share on Linkedin
Artificial sweeteners may be associated with a higher risk of cardiovascular disease (CVD), according to new research published in The BMJ. Aspartame intake was linked to a greater risk of cerebrovascular events and acesulfame potassium and sucralose were linked to a greater risk of coronary heart disease.
These findings, researchers wrote, suggest that artificial sweeteners "should not be considered a healthy and safe alternative to sugar."
READ MORE >

In Case You Missed It

Boston Scientific gains a new FDA approval for Watchman FLX LAAC device

The company can now update its labeling instructions for the device to include a new 45-day dual anti-platelet therapy treatment option when treating non-valvular atrial fibrillation. 

READ MORE >
Watchman FLX left atrial appendage closure (LAAC)
Share on Twitter Share on Facebook Share on Linkedin

Boston Scientific gains a new FDA approval for Watchman FLX LAAC device

Share on Twitter Share on Facebook Share on Linkedin
Watchman FLX left atrial appendage closure (LAAC)
The company can now update its labeling instructions for the device to include a new 45-day dual anti-platelet therapy treatment option when treating non-valvular atrial fibrillation. 
READ MORE >

VIDEO: Previewing TCT 2022 in Boston with Juan Granada

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston. 

READ MORE >
Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation (CRF) and assistant professor of medicine at Columbia University College of Physicians and Surgeons, explains some of the highlights of the upcoming 2022 Transcatheter Cardiovascular Therapies (TCT) conference sponsored by CRF. #TCT #TCT2022
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Previewing TCT 2022 in Boston with Juan Granada

Share on Twitter Share on Facebook Share on Linkedin
Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation (CRF) and assistant professor of medicine at Columbia University College of Physicians and Surgeons, explains some of the highlights of the upcoming 2022 Transcatheter Cardiovascular Therapies (TCT) conference sponsored by CRF. #TCT #TCT2022
Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston. 
READ MORE >

VIDEO: AI for stroke detection on CT imaging

Bibb Allen, MD, FACR, chief medical officer of the American College of Radiology (ACR) Data Science Institute, explains the trend of using AI for the automated detection of stroke on computed tomography (CT) imaging and the need to include radiologists on the stroke care team.

READ MORE >
Ischemic stroke shown in CT scans. Image courtesy of RSNA
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: AI for stroke detection on CT imaging

Share on Twitter Share on Facebook Share on Linkedin
Ischemic stroke shown in CT scans. Image courtesy of RSNA
Bibb Allen, MD, FACR, chief medical officer of the American College of Radiology (ACR) Data Science Institute, explains the trend of using AI for the automated detection of stroke on computed tomography (CT) imaging and the need to include radiologists on the stroke care team.
READ MORE >

VIDEO: TAVR for asymptomatic patients with severe calcific aortic stenosis

Philippe Genereux, MD, medical director of the Structural Heart Disease Program at Morristown Medical Center, discusses the use of transcatheter aortic valve replacement (TAVR) procedures in patients with severe, calcific aortic stenosis who are asymptomatic. 

READ MORE >
Balloon expansion deployment of an Edwards Lifesciences Sapien 3 transcatheter aortic valve replacement (TAVR) device.
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: TAVR for asymptomatic patients with severe calcific aortic stenosis

Share on Twitter Share on Facebook Share on Linkedin
Balloon expansion deployment of an Edwards Lifesciences Sapien 3 transcatheter aortic valve replacement (TAVR) device.
Philippe Genereux, MD, medical director of the Structural Heart Disease Program at Morristown Medical Center, discusses the use of transcatheter aortic valve replacement (TAVR) procedures in patients with severe, calcific aortic stenosis who are asymptomatic. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme